WATERTOWN, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 28 th Annual Roth Conference on Tuesday, March 15, 2016 at 1:00 p.m. Pacific Time at The Ritz Carlton Hotel in Orange County, California.

A live audio webcast of the Roth presentation will be available on the company's website at http://ir.tphase.com/events.cfm.  An archived presentation will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic candidates: eravacycline, its late-stage clinical candidate, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman	617-600-7040	tdahlman@tphase.comMedia Contact:Sam Brown Inc.Mike Beyer 312-961-2502mikebeyer@sambrown.comArgot PartnersSusan Kim212-600-1902susan@argotpartners.com

Primary Logo